JP7252895B2 - 結核菌シャペロニン６０．１ペプチドおよびその使用 - Google Patents

結核菌シャペロニン６０．１ペプチドおよびその使用 Download PDF

Info

Publication number
JP7252895B2
JP7252895B2 JP2019538337A JP2019538337A JP7252895B2 JP 7252895 B2 JP7252895 B2 JP 7252895B2 JP 2019538337 A JP2019538337 A JP 2019538337A JP 2019538337 A JP2019538337 A JP 2019538337A JP 7252895 B2 JP7252895 B2 JP 7252895B2
Authority
JP
Japan
Prior art keywords
seq
isolated
disease
peptide molecule
recombinant peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504161A (ja
Inventor
ライトフット，アンドリュー
クーパー，ニコラ
Original Assignee
レボロ バイオセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レボロ バイオセラピューティクス リミテッド filed Critical レボロ バイオセラピューティクス リミテッド
Publication of JP2020504161A publication Critical patent/JP2020504161A/ja
Priority to JP2022188982A priority Critical patent/JP2023029902A/ja
Application granted granted Critical
Publication of JP7252895B2 publication Critical patent/JP7252895B2/ja
Priority to JP2024196183A priority patent/JP2025032107A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
JP2019538337A 2017-01-12 2018-01-11 結核菌シャペロニン６０．１ペプチドおよびその使用 Active JP7252895B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022188982A JP2023029902A (ja) 2017-01-12 2022-11-28 結核菌シャペロニン６０．１ペプチドおよびその使用
JP2024196183A JP2025032107A (ja) 2017-01-12 2024-11-08 結核菌シャペロニン６０．１ペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1700557.0 2017-01-12
GBGB1700557.0A GB201700557D0 (en) 2017-01-12 2017-01-12 Novel peptides
PCT/GB2018/050072 WO2018130834A1 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188982A Division JP2023029902A (ja) 2017-01-12 2022-11-28 結核菌シャペロニン６０．１ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2020504161A JP2020504161A (ja) 2020-02-06
JP7252895B2 true JP7252895B2 (ja) 2023-04-05

Family

ID=58463310

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538337A Active JP7252895B2 (ja) 2017-01-12 2018-01-11 結核菌シャペロニン６０．１ペプチドおよびその使用
JP2022188982A Pending JP2023029902A (ja) 2017-01-12 2022-11-28 結核菌シャペロニン６０．１ペプチドおよびその使用
JP2024196183A Pending JP2025032107A (ja) 2017-01-12 2024-11-08 結核菌シャペロニン６０．１ペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022188982A Pending JP2023029902A (ja) 2017-01-12 2022-11-28 結核菌シャペロニン６０．１ペプチドおよびその使用
JP2024196183A Pending JP2025032107A (ja) 2017-01-12 2024-11-08 結核菌シャペロニン６０．１ペプチドおよびその使用

Country Status (9)

Country Link
US (1) US11098090B2 (https=)
EP (1) EP3568148B1 (https=)
JP (3) JP7252895B2 (https=)
CN (1) CN110381979A (https=)
AU (1) AU2018208077B2 (https=)
CA (1) CA3049353C (https=)
ES (1) ES2970436T3 (https=)
GB (1) GB201700557D0 (https=)
WO (1) WO2018130834A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023029902A (ja) * 2017-01-12 2023-03-07 レボロ バイオセラピューティクス リミテッド 結核菌シャペロニン６０．１ペプチドおよびその使用
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
US12378291B2 (en) 2017-01-12 2025-08-05 Revolo Biotherapeutics Limited Method for the treatment of allergic rhinitis

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331088B2 (en) 2017-01-12 2025-06-17 Revolo Biotherapeutics Limited Method for the treatment of a relapsing-remitting condition
EP4525906A1 (en) 2022-05-16 2025-03-26 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet
WO2024218571A1 (en) 2023-04-18 2024-10-24 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating eosinophilic esophagitis
WO2025037259A1 (en) 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating severe asthma
WO2025255468A2 (en) 2024-06-06 2025-12-11 Miguel Guzman Subcutaneous formulation of a peptide derived from chaperonin 60.1
WO2026024894A2 (en) 2024-07-24 2026-01-29 De Alba Jorge Sublingual formulations of a peptide derived from chaperonin 60.1 and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503382A (ja) 2003-08-22 2007-02-22 ディアトス （ソシエテ アノニム） 高分子量プロドラッグの活性化の可能性
JP2010502765A (ja) 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
JP2013510094A (ja) 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
JP2014532395A (ja) 2011-10-21 2014-12-08 ペプトイノベート リミテッド 新規ペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0226105D0 (en) 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0803369D0 (en) * 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503382A (ja) 2003-08-22 2007-02-22 ディアトス （ソシエテ アノニム） 高分子量プロドラッグの活性化の可能性
JP2010502765A (ja) 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
JP2013510094A (ja) 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
JP2014532395A (ja) 2011-10-21 2014-12-08 ペプトイノベート リミテッド 新規ペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Angiogenesis, 2011, Vol.14, pp.431-442

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023029902A (ja) * 2017-01-12 2023-03-07 レボロ バイオセラピューティクス リミテッド 結核菌シャペロニン６０．１ペプチドおよびその使用
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
US12378291B2 (en) 2017-01-12 2025-08-05 Revolo Biotherapeutics Limited Method for the treatment of allergic rhinitis

Also Published As

Publication number Publication date
US11098090B2 (en) 2021-08-24
EP3568148A1 (en) 2019-11-20
ES2970436T3 (es) 2024-05-28
GB201700557D0 (en) 2017-03-01
JP2023029902A (ja) 2023-03-07
CA3049353A1 (en) 2018-07-19
AU2018208077B2 (en) 2021-11-11
JP2025032107A (ja) 2025-03-11
EP3568148B1 (en) 2023-11-01
CA3049353C (en) 2024-10-29
AU2018208077A1 (en) 2019-07-25
CN110381979A (zh) 2019-10-25
EP3568148C0 (en) 2023-11-01
JP2020504161A (ja) 2020-02-06
WO2018130834A1 (en) 2018-07-19
US20200071365A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
JP7252895B2 (ja) 結核菌シャペロニン６０．１ペプチドおよびその使用
US11834478B2 (en) Method for the treatment of a relapsing-remitting condition
JP6199296B2 (ja) 新規ペプチド
US20260085098A1 (en) Method for the treatment of an acute respiratory distress syndrome
US12358957B2 (en) Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
CN106986927A (zh) 修饰肽及其用于治疗自体免疫疾病的用途
CA3049355C (en) Method for the treatment of a relapsing-remitting condition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191010

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221205

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230324

R150 Certificate of patent or registration of utility model

Ref document number: 7252895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250